$MRNA is set to report its latest quarterly results tonight. Although the stock just hit a new high a few days ago, discussions in the community are sharply divided, with expectations at the extremes ranging from a 20% gain to a 20% drop.
Typically, the third quarter is a traditional peak revenue season for the company, and the bar set by the capital markets is correspondingly high. Looking back at past results, the stock rose after just one of its last five third-quarter earnings releases.
There are three main things to watch in this earnings call: first, whether the company can maintain its full-year growth guidance of up to 10%; second, its operating cost controls and cash burn rate; and third, the pace of progress in the pipeline for intismeran in indications for other tumor types, such as kidney cancer.
A more in-depth analysis has also been posted on OKX Planet. On balance, I’m currently inclined to stay cautious and lean bearish.
Typically, the third quarter is a traditional peak revenue season for the company, and the bar set by the capital markets is correspondingly high. Looking back at past results, the stock rose after just one of its last five third-quarter earnings releases.
There are three main things to watch in this earnings call: first, whether the company can maintain its full-year growth guidance of up to 10%; second, its operating cost controls and cash burn rate; and third, the pace of progress in the pipeline for intismeran in indications for other tumor types, such as kidney cancer.
A more in-depth analysis has also been posted on OKX Planet. On balance, I’m currently inclined to stay cautious and lean bearish.